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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of penile rehabilitation interventions for post-prostatectomy erectile dysfunction.
B A C K G R O U N D
Prostate cancer is the most common non-skin cancer in men in
the UK, accounting for about 23% of all new diagnoses and 13%
of deaths (or about 35,000 new diagnoses and 10,000 deaths each
year) in England andWales (Bolland 2008). In the US, it accounts
for 186,320 new diagnoses and 28,660 deaths each year and is the
second leading cause of mortality in men (Jamal 2008; Goluboff
2013). Early stage prostate cancer is essentially a symptomless dis-
ease, particularly if the disease is confined to the prostate. For or-
gan-confined prostate cancer, treatment options with curative in-
tent include radical retropubic prostatectomy (RRP), robotic-as-
sisted radical prostatectomy (RARP), brachytherapy, and external
beam radiation therapy with or without concomitant hormone
treatment. Active surveillance of prostate cancer also falls into the
category of treatments with curative intent. This treatment ap-
proach consists of an active decision not to treat the prostate cancer
at the time of diagnosis but rather to monitor the patient closely
to enable the proper timing of curative treatment, taking into ac-
count the patient’s life expectancy. It is advocated by European
and American urological guidelines in patients with low risk or-
gan-confined prostate cancer (Heidenreich 2014). Radical prosta-
tectomy (RP) has the potential to completely remove the tumour
and remains a preferred and effective treatment modality utilised
as a first option in approximately 33% of prostate cancer cases
and in 52% of cases in men aged 62 years of age (Lalong-Muh
2012; American Cancer Society 2014). In 2010 in the US alone,
1Penile rehabilitation for post-prostatectomy erectile dysfunction (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
11,290 prostatectomies were performed, two-thirds of which were
robotic-assisted. These figures compared to the data from 2004,
when 6188 prostatectomies were performed, of which only eight
per cent were robotic-assisted, suggests that RP rates have risen
exponentially since the introduction of RARP (Lowrance 2012).
The common side-effects of RRP include erectile dysfunction
(ED) and urinary incontinence (Bolland 2008). Despite attempts
to preserve the neurovascular bundles with nerve-sparing surgery,
ED remains common. Even with nerve-sparing surgery, there is a
period of neuropraxia during which the man has no spontaneous
erections, which can lead to penile hypoxia and long-lasting dam-
age to the erectile tissue (Burnett 2005; Raina 2010). It is diffi-
cult to predict the length of time that neuropraxia will last, with
some researchers suggesting it is between 9 and 24 months (Zippe
2001). A goal of ED management is therefore to restore blood
flow (and oxygenation) to the penis at an early stage, with the hope
of preventing irreversible neuropraxia and penile shortening, and
hastening the recovery or preservation of pre-treatment erectile
function.
Post-operative penile rehabilitation has now become an integral
part of patient management after RP. First line strategies include
the use of phosphodiesterase type 5 inhibitors (PDE5Is) alone
or in combination at different strengths and dosing frequencies.
Other modalities include injectable medications, medicated ure-
thral systems for erections and vacuum pumps.
Description of the condition
ED is defined as the inability of a man to achieve and maintain an
erection of sufficient strength for satisfactory sexual activity (NIH
Consensus Conference 1993). The incidence of ED reported in
the literature after radical prostatectomy (RP) varies dramatically
from 20% to 90% (Fowler 1993; Rabbani 2000; Stanford 2000;
Kundu 2004; Rozet 2005; Penson 2008; Alemozaffar 2011). The
discrepancy in the reported rates of erectile function after RP is
due to many factors. These include variations in study population
demographics, means of data acquisition, variability in question-
naire use, duration of postoperative follow up, variations in base-
line erectile function status, inconsistency in defining adequate
erectile function, surgical technique, and the definition of quality
and consistency of erection (Mulhall 2009). ED can have a major
impact on the individual’s self-esteem, quality of life, confidence,
and life satisfaction, causing depression in certain cases (Kubin
2003). Quantifying accurately the prevalence of ED after RP is
of utmost importance in evaluating the burden of this treatment-
related adverse effect, in order to set appropriate expectations and
facilitate medical decision making. In a recent analysis, Mulhall
2009 identified 24 studies which originated from major cancer
centres and reported ED recovery outcomes post RP, in large pa-
tient cohorts. In these studies, the mean overall rates of erectile
function recovery were 48% ± 25% (range 12% to 96%). When
nerve sparing was accounted for, as it was in 14 (58%) of the 24
articles reviewed, mean erectile function recovery rates were 50%
± 24% for bilateral and 34% ± 16% for unilateral nerve-sparing
surgery.
Description of the intervention
Penile rehabilitation following RP revolves around the use of
medications (alone or in combination) and/or devices to pre-
serve erectile tissue health (Mulhall 2010). The treatment op-
tions include: phosphodiesterase type 5 inhibitors (sildenafil cit-
rate; tadalafil; vardenafil) ’as required’ or daily dosing (tadalafil);
alprostadil preparations (prostaglandin E1, such as Viridal Duo or
Caverject as injectables, or Medicated Urethral System for Erec-
tions (MUSE) as urethral pellets), and vacuum erection or vacuum
constriction devices (VED/VCD) (Steggall 2011; Weyne 2015).
These interventions have been used singly or in combination, ei-
ther pre-surgery or following successful trial without catheter fol-
lowing surgery, and at different strengths, dosing frequencies and
combinations, to attempt to identify the most suitable option to
prevent or limit neuropraxia, recover erections and restore sexual
activity.
How the intervention might work
The main pathophysiological mechanism which underlies the de-
velopment of ED after RP is damage to the cavernosal nerves.
Damage to these nerves occurs either due to their complete tran-
section during non-nerve-sparing procedures or due to neuro-
praxia which commonly occurs during nerve-sparing RP. Neu-
ropraxia is defined by the transient block of nerve transmission
despite an anatomically intact nerve, caused in this case by di-
rect trauma, stretching, heating, ischaemia and local inflammation
(Fode 2013). The direct effect of loss of cavernosal nerve function
causes a reduction in the oxygenation of penile tissues. This results
in loss of smooth muscle due to apoptosis (Kendirci 2006), im-
paired veno-occlusive function, collagen accumulation, and ulti-
mately penile fibrosis (Hatzimouratidis 2009; Kacker 2013). Col-
lectively these physiological changes result in ED and penile short-
ening.
Surgical intervention is known to induce hypoxia in a time-de-
pendent manner, such that the potential for recovery of erectile
function decreases with time. The goal of early intervention with
penile rehabilitation strategies is to improve the oxygenation of
cavernosal tissue during the period of neuropraxia, to prevent un-
inhibited deterioration of penile tissues and tominimise (if not ab-
rogate) the adverse structural and physiological changes that occur
in the penis followingRP. Penile rehabilitation also ensures that the
patient is well-placed to regain pre-surgery erectile function and
not remain dependent on erectile aids following surgery (Burnett
2013; Segal 2013). Oral PDE5 inhibitors (PDE5Is), by virtue of
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their ease of use, are often considered as the mainstay of EDman-
agement. They are generally well-tolerated, have proved to be rel-
atively safe and are the preferred treatment post-prostatectomy in
some centres. Nevertheless, there are a number of men with post
surgery ED, who do not respond to PDE5Is, or who become less
responsive and less satisfied as treatment progresses. In some men,
PDE5Is are contraindicated by virtue of the use of nitrate medica-
tion and the risk of consequent hypotension. Apart from the oral
PDE5Is, the other options for management of post-prostatectomy
ED (including MUSE and intracavernosal injections (ICIs)) are
invasive, uncomfortable, unappealing and sometimes ineffective
for some patients. Whilst PDE5Is may be appealing as they appear
’easy’ to use, there are limited data examining whether PDE5Is
aid penile rehabilitation in a time dependent manner, which is
critical as men often prefer to manage their incontinence before
their erections, and if treatment is not introduced early, there is
a risk of penile atrophy that will make the recovery of erections
more problematic.
Why it is important to do this review
ED is a common adverse event of RP and it significantly affects
quality of life. Effective, convenient andwell-tolerated penile reha-
bilitation interventions are important to minimise the incidence
of ED after RP. Over the years a multitude of different penile
rehabilitation strategies have been introduced which aim to im-
prove the oxygenation of penile tissues during the period of neu-
ropraxia that inevitably follows RP. Several randomised controlled
trials have been published which address the question of whether
these treatment modalities (alone or in combination) are of any
benefit in reducing the incidence of ED after RP. The purpose of
this review is to systematically evaluate these treatment options
and combinations to identify whether these interventions can re-
cover erections and restore sexual activity in addition to improving
other important clinical outcomes such as quality of life (QOL).
Our further aim is to compare, where evidence exists, different
treatment modalities to determine which of these treatments may
be most beneficial to patients suffering from post-prostatectomy
ED. This may help in the creation of a step-wise management
approach for patients with ED.
O B J E C T I V E S
To assess the effects of penile rehabilitation interventions for post-
prostatectomy erectile dysfunction.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include randomised controlled trials (RCTs) with a parallel
or cross-over design, and quasi-randomised controlled trials. In
the case of cross-over trials, only results from the first treatment
arm (if available) will be utilised in order to exclude any carry-over
effects (Elbourne 2002). Due to the nature of the review question,
we will not consider cluster-RCTs.
Types of participants
Male participants (aged 18 years or over), receiving radical surgi-
cal intervention for clinically organ-confined prostate cancer (cT1
or T2, N0 and M0) irrespective of disease risk status. We will
also consider patients with T3 disease who were treated by radical
prostatectomy (RP) alone and received no other form of adjuvant
or neoadjuvant therapy. We will consider all surgical approaches
of RP such as radical retropubic prostatectomy (RRP), radical per-
ineal prostatectomy, laparoscopic prostatectomy and RALP, irre-
spective of the nerve-sparing status. We will exclude patients who
have had RP as a salvage procedure following failed primary ther-
apy with another treatment modality.
We will also exclude patients who were administered androgen de-
privation therapy (ADT) or salvage radiotherapy due to biochem-
ical recurrence following RP. We will only include patients who
had erectile function sufficient for intercourse prior to surgery, as
documented by an International Index of Erectile Function (IIEF)
score. We define these patients as those who have IIEF or IIEF-
5 scores within the mild or no erectile dysfunction range (IIEF ≥
19 and IIEF-5 ≥ 17). We have chosen these baseline IIEF scores
as they include patients with mild and no erectile function which
we consider as having erectile function sufficient for intercourse.
Patients also need to have a heterosexual partner and be sexually
active. We will focus on men in heterosexual relationships since
it has been reported that anal intercourse requires 33% greater
penile rigidity (Gebert 2014). We will permit inclusion of studies
in whom a small subset of patients (less than 10%) do not meet
the IIEF or IIEF-5 score entry criterion as defined above, but we
will consider the outcome data from these studies in a separate
stratified analysis.
Types of interventions
We plan to investigate the following experimental versus compar-
ison interventions.
Experimental interventions
1. Phosphodiesterase type 5 inhibitors (PDE5Is) - sildenafil, var-
denafil and tadalafil ’as needed’
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2. PDE5Is - tadalafil 2.5mg or 5mg daily
3. PDE5Is - sildenafil or vardenafil daily
4. Prostaglandin E1 (alprostadil) administered as intracavernosal
injections (ICIs)
5. Prostaglandin E1 (alprostadil) administered intraurethrally -
Medicated Urethral System for Erections (MUSE) and Vitaros
(alprostadil topical cream)
6. Vacuum erection devices (VEDs) or vacuum constriction de-
vices (VCDs)
7. Combination treatments (e.g. PDE5Is and VEDs)
Comparator interventions
8. Placebo or no intervention/observation
Primary comparisons
For the primary outcomes of interest we will compare interven-
tions one to seven versus eight; where studies exist comparisons
will be made between the different interventions listed from one
to seven.
If appropriate studies are identified, we will report the secondary
subgroup comparisons of interventions one to eight.
We will include studies of psychological interventions only if these
are offered in combination with pharmacological interventions,
or are received by patients in both the intervention and control
groups.
Types of outcome measures
We will only consider trials with a minimum follow-up of six
weeks.
Primary outcomes
1. Number or percentage of patients achieving self-reported
potency after RP defined as an erection firm enough and of
sufficient duration to have sexual intercourse at six, 12 and 24
months;
2. Number or percentage of patients achieving potency after
RP according to IIEF and IIEF-5 scores at six, 12 and 24
months. For the IIEF-5 questionnaire, potency is defined as a
score ≥ 17 (out of 25) points. For the standard formal IEFF
questionnaire this is defined as a score of ≥ 19 (out of 30 points);
3. Rate of participants who suffered at least one serious adverse
event using an erectile aid (using the NCI Common Terminology
Criteria for Adverse Events (CTCAE) reporting; grades 3 to 5).
Secondary outcomes
1. Acceptability of the intervention (whether acceptable/
convenient to use by the patient) evaluated by Treatment
Acceptability Questionnaires (TAQ);
2. Rates of treatment discontinuation;
3. Quality of life and health-related quality of life using
validated questionnaires such as EDITS (Erectile Dysfunction
Inventory of Treatment Satisfaction) or QSF (Quality of Sexual
Function);
To assess the efficacy of these agents to potentially improve the
recovery of erectile function, patients of both groups being com-
pared need to be receiving no additional treatment for erectile
function or the same treatment (for example the same type and
dosage of a PDE-5 inhibitor).
Main outcomes for ’Summary of findings’ table
We will present a ’Summary of findings’ table reporting the fol-
lowing outcomes listed according to priority.
1. Patients achieving self-reported potency at six months
2. Patients achieving self-reported potency at 12 months
3. Patients achieving self-reported potency at 24 months
4. Patients achieving potency according to IIEF and IIEF-5
scores at six months
5. Patients achieving potency according to IIEF and IIEF-5
scores at 12 months
6. Patients achieving potency according to IIEF and IIEF-5
scores at 24 months
7. Participants who suffered at least one serious adverse event
(grades 3-5)
Search methods for identification of studies
Electronic searches
We will search for relevant references in:
• PubMed
• MEDLINE
• The Cochrane Central Register of Controlled Trials
(CENTRAL)
• CINAHL
• Embase
• PsycINFO
A list containing relevant search terms and search strategies (for
each database) will be generated separately. An exemplar search
strategy (MEDLINE via OvidSP) is provided in Appendix 1. The
search will be performed without language or data restrictions.
The search will be re-run within 12 months after publication and
include newly-identified studies in a further analysis.
The search terms used reflect the three components to our research
question:
A) interventions for ED;
B) ED variants;
C) RP for organ-confined prostate cancer.
The following search logic will be used:
A) Interventions for ED: both controlled vocabulary and key-
word searching related to drug interventions, including generic,
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chemical and brand names for pharmaceuticals listed in Types of
interventions section, as well as controlled vocabulary and key-
word searching for vacuum therapy and alternative interventions,
as described in the Types of interventions section. This will in-
clude variant terms and common abbreviations.
B) ED variants: both controlled vocabulary and keyword search-
ing related to erectile dysfunction and impotency, as well as the
converse (erectile function and potency) to avoid bias. Proximity
searching for sexual and quality of life, satisfaction, function, dys-
function, and other like terms will be incorporated to account for
all possible variations on ED.
C) RP for organ-confined prostate cancer: keyword and controlled
vocabulary searching for prostatectomy will be combined with
keyword and controlled vocabulary searching for prostatic neo-
plasms.
Searching other resources
• We will examine the reference lists of relevant obtained
articles, systematic reviews, and clinical practice guidelines, to
check for additional related published and unpublished studies.
• The Conference Proceedings Citation Index (available
through the Web of Science database) will be searched.
Additionally, specific conference proceedings for the British
Association of Urological Surgeons (BAUS); European
Association of Urology (EAU); and American Urological
Association (AUA) will also be searched (from 2008 onwards).
We have selected 2008 as a cut-off as most conference
proceedings are made available on international urological
associations’ websites from 2008 onwards.
• Consensus papers and proceedings from specialist meetings
(e.g. Sexual Function Health Council of the American
Foundation for Urologic Disease), will also be searched.
• We will contact experts in the field to enquire about any
relevant clinical trials or journal articles that are not listed in
other sources.
• We will also contact drug manufacturers, to enquire about
any relevant trials or journal articles that are not listed in other
sources.
Additionally, the following central registers of clinical trials will be
searched to identify any unpublished, ongoing or proposed new
trials:
• WHO International Clinical Trials Registry (apps.who.int/
trialsearch/)
• Current Controlled Trials (www.controlled-trials.com/)
• UK Clinical Research Network Portfolio Database (
public.ukcrn.org.uk/search/)
• UK Clinical Trials Gateway (www.ukctg.nihr.ac.uk/
default.aspx)
• ClinicalTrials.gov register (www.clinicaltrials.gov/)
• Current Controlled Trials (ISRCTN Register)
(www.controlled-trials.com/mrct/)
• ClinicalStudyResults.org (www.clinicalstudyresults.org)
Data collection and analysis
Selection of studies
We will use Covidence to identify and remove potential duplicate
records. Two review authors (YP, MS) will independently scan the
abstract, title, or both, of remaining records retrieved, to determine
which records should be assessed further. Two review authors (YP,
MS) will investigate all potentially-relevant records as full text,
map records to studies, and classify studies as included studies, ex-
cluded studies, studies awaiting classification, or ongoing studies,
in accordance with the criteria for each provided in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011b).
We will resolve any discrepancies through consensus or recourse to
a third review author (CTor PD). If resolution of a disagreement is
not possible, we will designate the study as ’awaiting classification’
and we will contact study authors for clarification. We will doc-
ument reasons for exclusion of studies that may have reasonably
been expected to be included in the review in a ’Characteristics
of excluded studies’ table. Studies will be included regardless of
whether outcomes are reported in a useable way. We will present
an adapted PRISMA flow diagram showing the process of study
selection (Liberati 2009).
Data extraction and management
Data will be extracted independently and in duplicate for each
trial/study by the authors (YP,MS). A data abstraction form based
on the standardised Cochrane data extraction form will be used.
We will also pilot test the data abstraction form in advance to
confirm its usability.
For studies that fulfil inclusion criteria, two review authors (YP,
MS) will independently abstract the following information, which
we will provide in the ’Characteristics of included studies’ table:
1. Study design;
2. Study dates (or report if these were not made available);
3. Participant details and baseline demographics;
4. Inclusion and exclusion criteria;
5. Number of participants by study/study arm;
6. Details of the intervention such as timing and dosage;
7. Definitions of outcomes, details of outcomes and how/
when they were measured, as well as any relevant subgroups;
8. Study funding sources;
9. Declarations of interest by the investigators.
We will resolve any disagreements regarding study characteristics
or outcome measures by discussion, or if required, by consultation
with a third review author (CT or PD).
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Assessment of risk of bias in included studies
The Cochrane tool for assessing risk of bias (Jüni 2001; Higgins
2011b) will be used to objectively assess the included studies. We
will judge the risk of bias on an outcome-specific basis as ’low
risk’, high risk’ or ’unclear risk’ for each of the following individual
items:
1. Sequence generation (selection bias);
2. Allocation concealment (selection bias);
3. Blinding of participants and personnel (performance bias);
4. Blinding of outcome assessors (detection bias);
5. Incomplete outcome reporting (attrition bias);
6. Selective outcome reporting;
7. Other biases.
Each ’Risk of bias’ determination will be made by three indepen-
dent members of the investigative team who will reach consensus
by discussion and if necessary, arbitration by an additional team
member. We will summarise these findings in a ’Risk of bias’ table
with the justification for the findings made transparent, including
information which is obtained outside of the publication, such as
from direct contact with the authors.
Measures of treatment effect
Where data are reported as dichotomous outcomes (e.g. achieve-
ment of potency), relative risk (RR) with 95% confidence interval
(CI) will be generated to express effect size of recovery rate and
ultimate recovery of erectile function, at various time points (three
months, six months and 12 months following initiation of treat-
ment regime) compared to no treatment or placebo, or between
two different treatment modalities.
For outcome scales (e.g. 15-IIEF, 5-IIEF, EDITS scores), ordinal
data will be assessed as continuous data. Mean differences will be
calculated where a mean and a standard deviation are provided or
can be generated. If different studies use different scales for the
same outcome measure the standardised mean difference (SMD)
will be calculated using Hedges’ g.
Unit of analysis issues
The unit of analysis will be the individual patient. In the case
of multiple intervention groups in a single trial, we will combine
groups to create a single pair-wise comparison; the approach rec-
ommended in the Cochrane Handbook.
Dealing with missing data
To obtain additional/missing data not reported in the articles, we
will contact the authors of papers. Where the data cannot be ob-
tained from the authors, or if the data are conflicting or we are
unable to pool the results, they will be discussed in view of the re-
sults obtained. For each included study, the number of drop-outs
(including their characteristics and reasons for dropping out), ex-
clusions from the analysis, or missing data, will be investigated and
reported. We plan to report an intention-to-treat analysis when-
ever possible. If the necessary data are not available, we will report
an available case analysis, which we will label as such. We will not
impute data.
Assessment of heterogeneity
We will identify heterogeneity (inconsistency) through visual in-
spection of the forest plots to assess the amount of overlap of CIs,
and the I2 statistic, which quantifies inconsistency across studies,
to assess the impact of heterogeneity on themeta-analysis (Higgins
2002; Higgins 2003). We will interpret I2 as follows.
• 0% to 40%: may not be important.
• 30% to 60%: may indicate moderate heterogeneity.
• 50% to 90%: may indicate substantial heterogeneity.
• 75% to 100%: considerable heterogeneity.
When we find heterogeneity, we will attempt to determine pos-
sible reasons for it by examining individual study and subgroup
characteristics. In the event of excessive heterogeneity unexplained
by subgroup analyses, we will not report study results as the pooled
effect estimate in a meta-analysis but will provide a narrative de-
scription of the results of each study.
Assessment of reporting biases
Sources of publication bias will be investigated and graphically
represented/summarised using standard methods (trial effect ver-
sus trial size), including funnel plots (after Egger 1997) if at least
10 studies report on a given outcome. Several explanations can
be offered for the asymmetry of a funnel plot, including true het-
erogeneity of effect with respect to trial size, poor methodological
design (and hence bias of small trials) and publication bias. We
will therefore interpret results with caution (Sterne 2011).
Data synthesis
Data from trials that are sufficiently similar andof sufficient quality
will be combined to provide pooled effect estimates.
When meta-analysis would be considered inappropriate, only a
narrative description of the study results will be provided.
Unless there is good evidence for homogeneous effects across stud-
ies, we will summarise data using a random-effects model (Wood
2008). We will interpret random-effects meta-analyses with due
consideration of the whole distribution of effects. In addition, we
will perform statistical analyses according to the guidelines con-
tained in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011a). For dichotomous outcomes, we will use
the Mantel-Haenszel method; for continuous outcomes, we will
use the inverse variance method. We will use Review Manager
(RevMan) software to perform analyses.
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Subgroup analysis and investigation of heterogeneity
We expect the following variables to be potential sources of het-
erogeneity and therefore plan to perform the following subgroup
analyses to determine potential qualitative or quantitative interac-
tions of the following subgroups with the effect estimate:
• Nerve-sparing approach (none versus unilateral or bilateral,
partial or complete nerve-sparing) since it may affect the
potential for recovery;
• Patient age (< 65 versus >=65 years); older patients may
have diminished recovery potential;
• Baseline erectile function scores (IIEF-5: 17 to 21 versus 22
to 25 or IIEF: 19 to 24 versus 25 to 30); patients with diminished
baseline function may have diminished recovery potential.
Subgroup analyses of the nerve-sparing approach will be impor-
tant to determine whether differences exist in effect estimate, if
any, of penile rehabilitation strategies on erectile function recov-
ery following RP between the subgroups. Age and baseline erec-
tile function scores are important co-variates which can affect the
degree of erectile function recovery offered by the penile rehabili-
tation strategies under investigation, and therefore it is important
to evaluate these in separate subgroup analyses.
Sensitivity analysis
We will perform a sensitivity analysis to assess the impact on the
effect estimate of excluding studies rated to be of high or unclear
risk of bias in terms of selection bias, performance bias or detec-
tion bias. In addition a sensitivity analyses will be performed if ap-
plicable to evaluate the impact on the effect estimate of excluding
quasi-randomised controlled studies.
’Summary of findings’ table
We will present the overall quality of the evidence for each out-
come according to the GRADE approach, which takes into ac-
count five criteria not only related to internal validity (risk of bias,
inconsistency, imprecision, publication bias) but also to external
validity such as directness of results (Guyatt 2011). Two review
authors (YP, PD) will independently rate the quality of evidence
for each outcome as ’high’, ’moderate’, ’low’, or ’very low’; discrep-
ancies will be resolved by consensus, or, if needed, by arbitration
by a third review author (CT or PD). We will present a summary
of the evidence for the main outcomes in a ’Summary of findings’
table, which provides key information about the best estimate of
the magnitude of the effect, in relative terms and absolute dif-
ferences for each relevant comparison of alternative management
strategies; numbers of participants and studies addressing each im-
portant outcome; and the rating of the overall confidence in effect
estimates for each outcome (Schünemann 2011). This will be ac-
complished in GRADEpro GDT. If meta-analysis is not possible,
we will present results in a narrative ’Summary of findings’ table.
We plan to present all three primary outcomes in our ’Summary
of findings’ table.
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A P P E N D I C E S
Appendix 1. Exemplar search strategy - MEDLINE (via OvidSP)
1. Alprostadil/
2. “Prostaglandin E1”.tw
3. alprostadil.tw
4. sildenafil.tw
5. viagra.tw
6. tadalafil.tw
7. cialis.tw
8. vardenafil.tw
9. levitra.tw
10. “penile rehabilitation”.tw
11. “erect$ rehabilitation”.tw
12. “vacuum therapy”.tw
13. “vacuum erection device$”.tw
14. VED.tw
15. “vacuum constriction device$”.tw
16. VCD.tw
17. exp Phosphodiesterase 5 Inhibitors/
18. (Phosphodiesterase adj1 “5 Inhibit$”).tw.
19. (Phosphodiesterase adj1 “V Inhibit$”).tw.
20. (PDE5 OR PDE-5 OR “PDE 5”) adj1 inhibit$.tw.
21. PDE5-I.tw
22. Muse$.tw
23. ICI.tw
24. “intracavernosal injection$”.tw.
25. OR/1-24
26. exp Erectile Dysfunction/
27. “erectile dysfunction”.tw
28. “erectile function”.tw
29. ED.tw
30. impoten$.tw
31. poten$.tw
32. ((sex or sexual$) adj3 (function$ or dysfunc$ or satisf$ or problem$ or symptom$ or arous$ or activ$ or rehabilitation OR “quality
of life”)).tw.
33. OR/26-32
34. exp Prostatectomy/
35. Prostatectom$.tw.
36. RP.tw
37. OR/34-36
38. exp Prostatic Neoplasms/
39. “prostate cancer”.tw.
40. “prostat$ neoplasm$”.tw.
41. CaP.tw.
42. OR/38-41
43. 37 AND 42
44. 25 AND 33 AND 43
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